Relmada Therapeutics (RLMD)
NASDAQ:RLMD
Holding RLMD?
Track your performance easily

Relmada Therapeutics (RLMD) Financial Statements

299 Followers

Relmada Therapeutics Financial Overview

Relmada Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.88; its P/E ratio is -1.15; Relmada Therapeutics is scheduled to report earnings on November 7, 2024, and the estimated EPS forecast is $-0.68. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Dec 23Sep 23Mar 23Dec 22
Income Statement-
Total Revenue-$ -96.40K-$ 96.40K-
Gross Profit-$ 83.60K-$ 276.40K$ -29.58M
EBIT$ -17.77M$ -26.83M$ -23.32M$ 29.99M$ -45.41M
EBITDA$ -17.77M$ -26.83M$ -23.32M$ 29.99M$ -45.41M
Net Income Common Stockholders$ -17.77M$ -25.17M$ -22.00M$ 29.99M$ -37.94M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 70.44M$ 96.32M$ 106.27M$ 132.44M$ 148.32M
Total Assets$ 71.03M$ 97.55M$ 109.15M$ 135.57M$ 152.91M
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -70.44M$ -96.32M$ -106.27M$ -132.44M$ -148.32M
Total Liabilities$ 9.54M$ 12.19M$ 8.42M$ 10.10M$ 12.47M
Stockholders Equity$ 61.49M$ 85.36M$ 100.73M$ 125.47M$ 140.44M
Cash Flow-
Free Cash Flow$ -13.26M$ -10.25M$ -11.63M$ -16.51M$ -35.88M
Operating Cash Flow$ -13.26M$ -10.25M$ -11.63M$ -16.51M$ -35.88M
Investing Cash Flow$ 14.01M$ 7.74M$ 3.86M$ 40.00M$ -1.66M
Financing Cash Flow-$ -98.46K--$ 409.88K
Currency in USD

Relmada Therapeutics Earnings and Revenue History

Relmada Therapeutics Debt to Assets

Relmada Therapeutics Cash Flow

Relmada Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis